ANI Pharmaceuticals ANIP Stockholders' Equity Attributable to Parent and Temporary Equity
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept anip:StockholdersEquityAttributableToParentAndTemporaryEquity.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's stockholders' equity attributable to parent and temporary equity.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ANI Pharmaceuticals's stockholders' equity attributable to parent and temporary equity?
- ANI Pharmaceuticals (ANIP) reported stockholders' equity attributable to parent and temporary equity of $562.3M in Q1 2026.
- How has ANI Pharmaceuticals's stockholders' equity attributable to parent and temporary equity changed year-over-year?
- ANI Pharmaceuticals's stockholders' equity attributable to parent and temporary equity increased by 26.8% year-over-year, from $443.47M to $562.3M.
- What is the long-term trend for ANI Pharmaceuticals's stockholders' equity attributable to parent and temporary equity?
- Over 4 years (2021 to 2025), ANI Pharmaceuticals's stockholders' equity attributable to parent and temporary equity has grown at a 10.8% compound annual growth rate (CAGR), from $358.74M to $540.72M.